Lymphoma Working Party (LWP)
Study type:
Study number:
84032237
Type of treatment:
CAR T
Diseases:
Non-Hodgkin’s Lymphoma (NHL)
Short title:
RWE CAR-T in FL
Primary objective:
Efficacy and toxicity of CAR-T therapy for FL in a real-world setting.
Key inclusion criteria:
• Patients with FL treated with commercial CAR-T therapy and included in the EBMT registry.
• Patients with FL treated with CAR-T therapy on a compassionate use program, hospital exemption or within a clinical trial included in the EBMT registry will be added.
• Patients with FL treated with CAR-T therapy on a compassionate use program, hospital exemption or within a clinical trial included in the EBMT registry will be added.
Country:
All EBMT member countries
Principal investigator:
Dr. Leyre BENTO & Dr. Silvia MONTOTO
EBMT Study coordinator:
Diane Marie BACABAC
Study coordinator email:
diane.bacabac@ebmt.org
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results